Reimmunization after blood or marrow stem cell transplantation
Reimmunization after blood or marrow stem cell transplantation
复制标题
DOI：
10.1038/sj.bmt.1701640
复制
发表时间：
1999-04
影响因子：
4.8
通讯作者：
S. Singhal;J. Mehta
中科院分区：
文献类型：
--
作者：
S. Singhal;J. Mehta
在异基因和自体血液和骨髓移植后，对可通过常规疫苗接种预防的疾病的保护性免疫力随着时间的推移而丧失。同种异体移植后从供者向受者过继转移免疫不足以防止这种下降。移植后需要在适当的时间间隔进行系统的再免疫，以重新建立免疫力。对疫苗接种的反应取决于移植的类型、细胞来源、患者的免疫状态和正在使用的疫苗。虽然灭活疫苗或亚单位疫苗在所有移植受者中都是安全的，但活疫苗通常是禁忌的。不同移植中心的再免疫做法差别很大。这项全面的综述总结了已发表的移植后疫苗接种数据，并在此基础上提出了可用作开发再免疫方案的框架的指南。
Protective immunity to diseases preventable by routine vaccination is lost over time following allogeneic and autologous blood and marrow transplantation. Adoptive transfer of immunity from donors to recipients after allogeneic transplantation is not sufficient to prevent this decline. Systematic reimmunization is necessary at appropriate time intervals following transplantation to re-establish immunity. Response to vaccination depends upon the type of transplant, the source of cells, the immune status of the patient, and the vaccine being used. While inactivated or subunit vaccines are safe in all transplant recipients, live vaccines are generally contraindicated. Reimmunization practices vary widely amongst transplant centers. This comprehensive review summarizes published data on post-transplant vaccination, and based upon these, suggests guidelines which may be used as a framework for development of reimmunization protocols.